Genmab shares spike on fresh rumors of a Glaxo takeover

A little fresh speculation regarding some old talk about a possible GlaxoSmithKline takeover of Genmab inspired a spike in the Denmark developer's share price. "The stock value is so low it makes sense for GSK to make an offer for the entire company," analyst Peter Aabo told Bloomberg. Aabo calculated that with a market price of $373 million, only twice the amount of cash on its books, Genmab partner GlaxoSmithKline could easily snap it up. The two companies are collaborating on the cancer drug...